Isomorphic Labs, an AI-powered drug discovery company spun out of Alphabet’s (GOOGL) GoogleDeepMind, is in advanced talks to raise more than $2B in a new round of funding, people familiar with the matter told Bloomberg’s Rebecca Torrence and Mark Bergen. Thrive Capital, which led Isomorphic’s first funding round last year, is set to lead the new financing and Alphabet is also participating, according to the report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GOOGL:
- Nuro Secures California Driverless Permit as Tesla (TSLA) Robotaxis Remain Supervised
- Alphabet Stock Forecast — 10 Top Financial Analysts Reaffirm Bullish Stance on GOOGL after Q1 Double-Beat
- Broadcom (AVGO) Stock Rallies on Potential $35B Deal, the Largest Private Credit Transaction Ever
- Akamai Stock (AKAM) Soars on $1.8B Cloud Deal with Anthropic as AI Demand Surges
- AI Daily: Anthropic weighs raising funds at nearly $1T valuation